TR200200838T2 - İmmunolojik olarak önemli herpes simpleks virüs antijenleri. - Google Patents

İmmunolojik olarak önemli herpes simpleks virüs antijenleri.

Info

Publication number
TR200200838T2
TR200200838T2 TR2002/00838T TR200200838T TR200200838T2 TR 200200838 T2 TR200200838 T2 TR 200200838T2 TR 2002/00838 T TR2002/00838 T TR 2002/00838T TR 200200838 T TR200200838 T TR 200200838T TR 200200838 T2 TR200200838 T2 TR 200200838T2
Authority
TR
Turkey
Prior art keywords
antigens
cells
hsv
herpes simplex
simplex virus
Prior art date
Application number
TR2002/00838T
Other languages
English (en)
Inventor
M. Koelle David
Chen Hongbo
Corey Lawrence
Ann Hosken Nancy
Mcgowan Patrick
P. Fling Steven
M. Posavad Christine
Original Assignee
University Of Washington
Corixa Corporation
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington, Corixa Corporation, Fred Hutchinson Cancer Research Center filed Critical University Of Washington
Publication of TR200200838T2 publication Critical patent/TR200200838T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Bulus, HSV enfeksiyonunun tedavisi ve önlenmesi için yararli HSV antijenlerini saglamaktadir. Herpetik lezyonlardan türetilen T-hücreleri tarafindan tanindigi dogrulanan epitoplar burada ifsa edilmistir. Bulusun antijenleri için özellige sahip T hücreleri virütük olarak kodlanmis peptid epitoplarin ile yüklenmis hücrelere, çogu kez de HSV ile enfekte olmus hücrelere karsi sistotoksik aktivite göstermistir. T-hücrelerinin özelliginden sorumlu immünojenik antijenlerin belirlenmesi virütik karsiti tedavi edici ve koruyucu stratejilerin gelistirilmesini saglar. Bulusun antijenleri veya bu antijenleri kodlayan polinükleotidleri HSV enfeksiyonunun önlenmesi ve tedavisi için etkin hedeflenmis asilar saglamaktadir.
TR2002/00838T 1999-09-30 2000-09-28 İmmunolojik olarak önemli herpes simpleks virüs antijenleri. TR200200838T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15718199P 1999-09-30 1999-09-30
US20366000P 2000-05-12 2000-05-12
US21810400P 2000-07-13 2000-07-13

Publications (1)

Publication Number Publication Date
TR200200838T2 true TR200200838T2 (tr) 2002-06-21

Family

ID=27387973

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00838T TR200200838T2 (tr) 1999-09-30 2000-09-28 İmmunolojik olarak önemli herpes simpleks virüs antijenleri.

Country Status (16)

Country Link
US (2) US6413518B1 (tr)
EP (1) EP1222281B1 (tr)
JP (2) JP2003512305A (tr)
KR (1) KR20020048944A (tr)
CN (1) CN1376201A (tr)
AT (1) ATE345389T1 (tr)
AU (2) AU782676B2 (tr)
BR (1) BR0014408A (tr)
CA (1) CA2379623C (tr)
DE (1) DE60031874D1 (tr)
HK (1) HK1044799A1 (tr)
NO (1) NO20021479L (tr)
NZ (2) NZ517959A (tr)
PL (1) PL355265A1 (tr)
TR (1) TR200200838T2 (tr)
WO (1) WO2001023414A2 (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1102790B1 (en) * 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
EP1420821B8 (en) * 2001-07-31 2011-02-02 University of Washington Immunologically significant herpes simplex virus antigens and methods for using same
ATE494907T1 (de) * 2002-07-18 2011-01-15 Univ Washington Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
BR0315810A (pt) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
EP2289547B1 (en) * 2003-09-12 2015-12-16 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
CA2567491A1 (en) * 2004-05-24 2005-12-15 Baylor Research Institute Immune response assessment method
ATE514775T1 (de) 2006-02-08 2011-07-15 Illumina Cambridge Ltd Endenmodifikation zur verhinderung einer überrepräsentierung von fragmenten
WO2008011609A2 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2408812B1 (en) 2009-03-17 2015-12-16 CardioVax, LLC Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions
WO2010115172A2 (en) * 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
NZ597182A (en) * 2009-05-22 2014-07-25 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2305277A1 (en) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
AU2010319323B2 (en) 2009-11-14 2015-01-15 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
JP2013544243A (ja) 2010-11-12 2013-12-12 シーダース シナイ メディカル センター 動脈瘤の治療及び／又は予防のための免疫調節方法及びシステム
JP2014516913A (ja) 2010-11-12 2014-07-17 シーダース シナイ メディカル センター 高血圧の治療及び／又は予防のための免疫調節方法及びシステム
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2012212264B2 (en) * 2011-01-31 2016-01-28 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
RU2737530C1 (ru) * 2011-11-11 2020-12-03 Вэриэйшн Биотекнолоджиз, Инк. Композиции и способы для лечения цитомегаловируса
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
EP3160997B1 (en) * 2014-06-26 2020-10-28 Heidelberg ImmunoTherapeutics GmbH Topical application for an anti-hsv antibody
WO2017070623A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
BR112019014406A2 (pt) * 2017-01-20 2020-04-28 Atara Biotherapeutics Inc métodos de tratar esclerose múltipla usando células t autólogas
WO2022036103A1 (en) * 2020-08-13 2022-02-17 Rootpath Genomics, Inc. Compositions and methods for antigen identification
US20240174986A1 (en) * 2021-03-29 2024-05-30 Rational Vaccines, Inc. Mutant herpesvirus and vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
EP0541692B1 (en) 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
EP0845043B1 (en) 1995-07-28 2007-06-27 Marie Curie Cancer Care Transport proteins and their uses
CA2270282A1 (en) * 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
CA2291010A1 (en) * 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6169175B1 (en) * 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
AU3102799A (en) * 1998-03-20 1999-10-11 Genzyme Corporation Enhanced anti-tumor immunity

Also Published As

Publication number Publication date
NO20021479L (no) 2002-05-03
BR0014408A (pt) 2002-07-02
WO2001023414A3 (en) 2001-11-08
WO2001023414A2 (en) 2001-04-05
US6413518B1 (en) 2002-07-02
ATE345389T1 (de) 2006-12-15
JP5602188B2 (ja) 2014-10-08
HK1044799A1 (zh) 2002-11-01
JP2003512305A (ja) 2003-04-02
EP1222281B1 (en) 2006-11-15
US6962709B2 (en) 2005-11-08
CA2379623C (en) 2014-09-09
EP1222281A2 (en) 2002-07-17
AU2005234654A1 (en) 2005-12-15
AU782676B2 (en) 2005-08-18
JP2012214478A (ja) 2012-11-08
US20020155122A1 (en) 2002-10-24
NZ531980A (en) 2005-04-29
NZ517959A (en) 2004-05-28
WO2001023414B1 (en) 2002-02-28
CN1376201A (zh) 2002-10-23
AU7836400A (en) 2001-04-30
NO20021479D0 (no) 2002-03-25
DE60031874D1 (de) 2006-12-28
KR20020048944A (ko) 2002-06-24
CA2379623A1 (en) 2001-04-05
AU2005234654B2 (en) 2008-04-24
PL355265A1 (en) 2004-04-05

Similar Documents

Publication Publication Date Title
TR200200838T2 (tr) İmmunolojik olarak önemli herpes simpleks virüs antijenleri.
TR200100373T2 (tr) İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
DK1523582T3 (da) Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
HUP0202804A2 (hu) Új készítmény
EP1017791A4 (en) RECOMBINANT RSV VIRUS EXPRESSION SYSTEM AND VACCINES
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
DE69735062D1 (de) Impfstoffherstellung des bacillus anthracis schutzantigens
ATE234628T1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
DK1272652T3 (da) Herpesvirus til immunmodulation
TR199801531T2 (tr) Zoster virüs geni ve ürününe karsi asilar.
DE60035695D1 (de) Schutzantigen des epstein-barr-virus
Lasky From virus to vaccine: recombinant mammalian cell lines as substrates for the production of herpes simplex virus vaccines
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
WO2003104262A3 (en) GP41 PEPTIDES AND METHODS USING SUCH PEPTIDES TO INHIBIT HIV FUSION WITH TARGET CELLS
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
SE9600436D0 (sv) Vaccine against hantavirus
ES2105984A1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
PL435261A1 (pl) Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19
Thomson IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE.
Allen et al. 720. EGFRvIII Retargeted Oncolytic Measles Virus Strains Have Significant Antitumor Activity Against Gliomas
WO2000018430A3 (en) Live virus vaccines to protect primates from hiv-1 infection and disease
AP2001002354A0 (en) Use of antibodies recognizing the interleukin-2 receptor in the prevention and /or treatment of infections by the AIDS viruses.